Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The long-acting regimen will enable some adolescents to take their HIV treatment just six times a year.
Disparities in who gets a PrEP prescription and who doesn’t show up even among those with access to care.
Immigrants and girls had worse HIV outcomes in this study.
The small single-site study will need to be replicated in a larger group of adolescents.
Better integration and transition planning was associated with higher rates of viral suppression among youth with HIV.
Supporting universal access to care and quality-of-life check-ins may be associated with better quality of life for teens with HIV.
The number of days to an undetectable viral load dropped by nearly two weeks, but there’s more work to do.
The Pfizer-BioNTech vaccine was 100% effective in a study of adolescents; trials for younger children are now underway.
However, even as new cases climbed, deaths declined.
Compared with efavirenz-based regimens, dolutegravir-containing ones resulted in fewer switches and better viral control.
An estimated 34 to 44 million adults at increased risk for the virus have a connection to schools.
What happens when a girl with HIV wants to have sex? The answer lies in Camryn Garrett’s “Full Disclosure.”
This special issue is dedicated to young people, who represent a majority of new HIV cases.
Researchers have called for improved communication about sexual orientation and HIV testing between pediatricians and adolescents.
A recent NIH study found that adults have a much higher viral suppression rate than youth.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.